Advancing to Third-Line Therapy: Belumosudil in cGVHD

Opinion
Video

Panelists discuss how belumosudil serves as a third-line therapy option for patients with chronic graft-versus-host disease (cGVHD), exploring its role in advancing treatment when earlier options have been exhausted.

Newsletter

Stay up to date on practice-changing data in community practice.

Recent Videos
1 expert in this video
1 expert in this video
3 experts are featured in this series.
1 expert in this video
3 experts are featured in this series.
1 expert in this video
3 experts are featured in this series.
3 experts are featured in this series.